Biotechnology · Nasdaq: MRNA
Moderna earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 12 Feb 2027
Latest: Q3 2026
Moderna won FDA approval for mFLUSIVA, its fifth approved product and the first mRNA flu vaccine, and reported positive Phase 3 intismeran melanoma results with Merck.
Moderna added its fifth approved product when the FDA approved mFLUSIVA, its mRNA seasonal flu vaccine, for adults 50 and older. The U.S. launch is limited this season because approval came after the annual contracting cycle. Demand for updated COVID vaccines was strong, driven by international government partnerships and growing U.S. uptake of mNEXSPIKE. Intismeran, developed with Merck, also showed a 42% reduction in the risk of recurrence or death in melanoma when added to KEYTRUDA.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $966.0M * |
| Q1 2025 | $108.0M |
| Q2 2025 | $142.0M |
| Q3 2025 | $1.0B |
| Q4 2025 | $678.0M * |
| Q1 2026 | $389.0M |
| Q2 2026 | $145.0M |
| Q3 2026 | $1.3B |
Data
| Q1 2025 | -$2.52 |
| Q2 2025 | -$2.13 |
| Q3 2025 | -$0.51 |
| Q1 2026 | -$3.40 |
| Q2 2026 | -$1.97 |
| Q3 2026 | $0.38 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | -129.0% |
| Q1 2025 | -972.2% |
| Q2 2025 | -638.7% |
| Q3 2025 | -25.6% |
| Q4 2025 | -126.4% |
| Q1 2026 | -356.8% |
| Q2 2026 | -562.1% |
| Q3 2026 | 9.9% |
Data
| Q4 2024 | $303.0M |
| Q1 2025 | -$1.2B |
| Q2 2025 | -$922.0M |
| Q3 2025 | -$880.0M |
| Q4 2025 | $891.0M |
| Q1 2026 | -$692.0M |
| Q2 2026 | -$563.0M |
| Q3 2026 | -$1.6B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $966.0Md | $108.0M | $142.0M | $1.0B | $678.0Md | $389.0M | $145.0M | $1.3B |
| Operating income | -$1.2Bd | -$1.1B | -$907.0M | -$260.0M | -$857.0Md | -$1.4B | -$815.0M | $130.0M |
| Operating margin | -129.0% | -972.2% | -638.7% | -25.6% | -126.4% | -356.8% | -562.1% | 9.9% |
| Net income | -$1.1Bd | -$971.0M | -$825.0M | -$200.0M | -$826.0Md | -$1.3B | -$782.0M | $162.0M |
| Diluted EPS | — | -$2.52 | -$2.13 | -$0.51 | — | -$3.40 | -$1.97 | $0.38 |
| Operating cash flow | $825.0Md | -$1.0B | -$919.0Md | -$847.0Md | $930.0Md | -$630.0M | -$526.0Md | -$1.6Bd |
| Capital expenditure | $522.0Md | $117.0M | $3.0Md | $33.0Md | $39.0Md | $62.0M | $37.0Md | $47.0Md |
| Free cash flow | $303.0M | -$1.2B | -$922.0M | -$880.0M | $891.0M | -$692.0M | -$563.0M | -$1.6B |
| R&D expense | $1.1Bd | $856.0M | $700.0M | $801.0M | $775.0Md | $649.0M | $651.0M | $583.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 6 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 31 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 1 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 20 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 6 Nov 202510-Q for the period ended 30 Sep 2025SEC ↗
- 1 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 1 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 21 Feb 202510-K for the period ended 31 Dec 2024SEC ↗